How Boldenone Undecylenate (EQ) Affects HDL Cholesterol

Boldenone suppresses HDL through two partially independent pathways:

1. Direct androgenic HTGL upregulation: Like all androgens, boldenone stimulates hepatic triglyceride lipase (HTGL) through androgen receptor activation in hepatocytes. This accelerates HDL catabolism and reduces circulating HDL. This is the common pathway shared by all AAS.
2. Indirect estradiol lowering via aromatase competition: Boldenone's 5-alpha-reduced metabolite, 1-testosterone (dihydroboldenone), competes for aromatase binding, inhibiting the conversion of testosterone to estradiol when boldenone is run alongside testosterone. This functional aromatase inhibition lowers estradiol. Lower estradiol removes the normal estrogenic brake on HTGL activity, accelerating HDL catabolism through the same mechanism as anastrozole or letrozole.
3. Additive dual mechanism: The direct androgenic stimulation and the indirect estradiol-mediated HTGL disinhibition act simultaneously. Users running EQ with testosterone often notice crashed estradiol at EQ doses above 400-600 mg/week, which compounds the HDL suppression beyond what either compound would cause alone.
4. No 17-alpha-alkylation: Boldenone is injectable and lacks the 17-AA structure, so it does not produce the same concentrated first-pass hepatic androgenic hit as oral steroids. The absence of first-pass toxicity is why EQ is genuinely milder than oral 17-AA compounds, but this does not mean it is mild in absolute terms.

At 300-600 mg/week:

• Expect 15-30% HDL reduction from baseline
• At 400 mg/week with 250 mg/week testosterone: combined HDL suppression often reaches 25-35% if estradiol is not actively managed
• Estradiol may fall to suboptimal levels (below 20 pg/mL) at the higher end of this range

At 800+ mg/week:

• HDL reduction of 30-45% or more from baseline
• Estradiol is commonly crashed at these doses when used alongside testosterone
• The dual-pathway HDL suppression becomes clinically significant; HDL below 30 mg/dL is possible

Comparison context:

• HDL impact is typically less than oral 17-AA compounds (stanozolol, oxymetholone) but more than testosterone alone at equivalent androgenic doses, partly due to the estradiol-lowering effect
• The EQ:testosterone ratio matters; a low test:EQ ratio (e.g., 1:2) will crash estradiol more than a 2:1 test:EQ ratio

Test HDL and estradiol together:

• Estradiol is essential to interpret HDL changes on EQ cycles; suppressed estradiol explains a disproportionate HDL drop
• If using EQ with testosterone, monitor for crashed estradiol (below 20 pg/mL)

Timing:

• Baseline lipid panel before starting
• Recheck at week 6-8 of the cycle
• Post-cycle recheck at 4-6 weeks after last EQ injection (boldenone's long half-life means effects persist for weeks post-injection)

Flags:

• HDL below 30 mg/dL with estradiol below 20 pg/mL on EQ: increase testosterone-to-EQ ratio or reduce EQ dose
• HDL below 25 mg/dL: consider stopping EQ

Run testosterone at a higher ratio than EQ:

• A minimum 2:1 test:EQ ratio (e.g., 500 mg test, 250 mg EQ) helps maintain adequate estradiol to counteract EQ's aromatase-competitive effect
• Some users find that reducing EQ and allowing estradiol to remain higher restores HDL better than adding an AI

Avoid stacking aggressive AI with EQ:

• EQ already lowers estradiol. Adding anastrozole or letrozole on top creates triple suppression of estradiol, dramatically worsening HDL via the HTGL disinhibition pathway.
• If using EQ, rely on lower AI doses and use estradiol levels to guide decisions rather than targeting a fixed AI dose

Supplement support:

• Omega-3 fatty acids (EPA/DHA 3-4 g/day)
• Citrus bergamot 500-1,000 mg/day
• If HDL drops below 25 mg/dL, consider reducing EQ dose before increasing supplements

Cycle length consideration:

• EQ is typically run 14-20 weeks due to its long undecylenate ester. This is a prolonged period of HDL suppression; the cardiovascular risk is cumulative. Shorter EQ cycles (10-12 weeks) reduce cumulative exposure.